About
This is a clinical research group focused on the diagnostics and treatment of medical complications of Substance Use Disorder (SUD). The group performs patient-centred research on the most frequent clinical complications. Its main objective is to deepen the knowledge of SUD and the associated complications. Its researchers pay special attention into alcohol, cocaine, cannabis, opiates and tobacco.
The SUD treatment is performed in the framework of a general and university hospital that provides secondary prevention for those that have recovered from a medical complication. The group is part of a research state platform (Redes de Investigación Cooperativa Orientada a Resultados en Salud -RICORS- / Red de Investigación en Atención Primaria de Adicciones -RIAPAd-). RIAPAd is constituted by 18 research groups whose objectives are to analyse the pathophysiology, clinical manifestations, and sanitary impact of SUD to ultimately provide tools for therapeutic and other interventions in order to help reduce the impact of substance use in society.
The group is also recognised as a Consolidated Research Group by the AGAUR, Generalitat de Catalunya (2021 SGR 00945, 2017 SGR 316) and in 2022 has participated in five different projects and led one.
Keywords: Addiction medicine, Substance Use Disorder, medical complications, Alcohol Use Disorder
_1686651085.jpg)
Group Leader
Research lines
Medical complications of alcohol use disorder
To characterize medical comorbidity of patients requesting treatment for alcohol use disorder: Alcoholic liver disease, immunological alterations, malnutrition, cardiovascular risk, neurological risk and viral infections, amongst other pathologies being studied.
Alcohol-associated morbidity and mortality
To describe the long-term evolution and outcomes of patients who abuse drugs or alcohol and knowing the causes of death as a function of comorbidity.
Therapeutic interventions in alcohol use disorder
Monitoring viral infections (HCV, HIV, HBV) in patients with SUD
- To establish diagnostics, clinical evaluation and access to treatment of common viral infections (i.e., HIV, Hepatitis B and C) in patients with substance use disorder
- To analyze the risk of developing disease such as AIDS, liver cirrhosis or cancer and death
Intestinal permeability, systemic inflammation and cardiometabolic alterations
To study markers of inflammation, intestinal permeability and oxidative stress in a cohort of patients with alcohol use disorder.
Immune alterations associated with alcohol use disorder
To characterize the alterations of cellular immunity subsets in patients with alcohol use disorder according to the severity of alcoholic liver disease and to determine the molecular mechanisms that make alcohol use disorder at risk of immunodeficiency.
Active projects
Alcoholic hepatitis: immunophenotypes, plasmatic protein expression and RNA sequencing at early diagnose of patients with alcohol use disorder
PI: Paola Zuluaga, Robert Muga
Programme: Fondo de Investigación en Salud (FIS)
Funding agency: Instituto de Salud Carlos III (ISCIII)
Agency code: PI20/00883
This research line analyses immunity activation phenotypes, the lymphocyte differentiation, and the role of specific serum proteins involved in the hepatic inflammatory reaction of patients with Alcohol Use Disorder (AUD).
Intestinal microbiota and alcohol use disorder. Impact of sex and concomitant use of cocaine and/or cannabis
PI: Daniel Fuster
Programme: Fondo de Investigación en Salud (FIS)
Funding agency: Ministerio de Sanidad, Plan Nacional Sobre Drogas.
Agency code: PNSD 2020I024
This research analyses immunity activation phenotypes, the lymphocyte differentiation, and the role of specific serum proteins involved in the hepatic inflammatory reaction of patients with Alcohol Use Disorder (AUD).
Multicentric study of adult people with alcohol use disorder that seek treatment for the first time (CohRTA Study)
PI: Robert Muga
Funding agency: Ministerio de Sanidad, Plan Nacional Sobre Drogas.
Agency code: PNSD 2018I020.
The objective of this study conducted in 9 Spanish centres is to collect clinical information in a wide series of AUD patients that start treatment for the first time and to analyse its impact on health.
Red de Trastornos Adictivos. Redes Temáticas de Investigación Cooperativa en Salud (RETICS)
PI: Robert Muga
Funding agency: Instituto de Salud Carlos III (ISCIII). Ministerio de Ciencia y Competitividad
Agency code: RD16/0017/0003
Redes de Investigación Cooperativa Orientada a Resultados en Salud (RICORS)
PI: Robert Muga
Funding agency: Instituto de Salud Carlos III (ISCIII), financed by NextGenerationEU
Agency code: RD21/0009/0004
Ajuts per donar suport a les activitats dels grups de recerca (SGR 2017-2019). Grup de Recerca Consolidat
PI: Robert Muga
Funding agency: Departament de Recerca i Universitats, Agència de Gestió d'Ajuts Universitaris i de Recerca (AGAUR)
Agency code: 2021 SGR 00945
Uso inapropiado de opioides en pacientes con cáncer de pulmón
PI: Teresa Morán
Funding agency: Sociedad Española de Oncología Médica
Diferencias en susceptibilidad genética a trastornos por uso de alcohol en función del sexo/género: implicaciones en tratamiento y pronóstico
PI: Javier Costas
Funding agency: Ministerio de Sanidad, Servicios Sociales e Igualdad, Plan Nacional Sobre Drogas
Agency code: 2021 SGR 00945
This project aims to identify genetic evidences of the prevalence of different pathways towards Alcohol Use Disorder (AUD) in men and women and to detect interactions between genotype (by Polygenic Risk Scores) and sex/gender in predicting the severity of AUD, polydrug use and psychiatric comorbidity
Scientific publications
Novo-Veleiro I et al.; Wernicke-SEMI Group, Alcohol and Alcoholism Group, Spanish Society of Internal Medicine (SEMI). Alcoholic Liver Disease Among Patients with Wernicke Encephalopathy: A Multicenter Observational Study. Drug Alcohol Depend. 2022 Jan 1;230:109186. DOI: 10.1016/j.drugalcdep.2021.109186. PMID: 34864357.
Hernández-Rubio A, Sanvisens A, Bolao F, Cachón-Suárez I, Garcia-Martín C, Short A, Bataller R, Muga R. Prevalence and associations of metabolic syndrome in patients with alcohol use disorder. Sci Rep. 2022 Feb 16;12(1):2625. DOI: 10.1038/s41598-022-06010-3. PMID: 35173187; PMCID: PMC8850419.
Alías-Ferri M, Pellegrini M, Marchei E, Pacifici R, Rotolo MC, Pichini S, Pérez-Mañá C, Papaseit E, Muga R, Fonseca F, Torrens M, Farré M. New Psychoactive Substances Consumption in Opioid-Use Disorder Patients. Biology (Basel). 2022 Apr 22;11(5):645. DOI: 10.3390/biology11050645. PMID: 35625373; PMCID: PMC9138226.
Alías-Ferri M, Pellegrini M, Marchei E, Pacifici R, Rotolo MC, Pichini S, Pérez-Mañá C, Papaseit E, Muga R, Fonseca F, Farré M, Torrens M. Synthetic cannabinoids use in a sample of opioid-use disorder patients. Front Psychiatry. 2022 Aug 3;13:956120. DOI: 10.3389/fpsyt.2022.956120. PMID: 35990071; PMCID: PMC9381952.
Zuluaga P, Teniente-Serra A, Fuster D, Quirant-Sánchez B, Hernandez-Rubio A, Martínez-Cáceres E, Muga R. Increased Natural Killer Cells Are Associated with Alcohol Liver Fibrosis and with T Cell and Cytotoxic Subpopulations Change. J Clin Med. 2022 Jan 8;11(2):305. DOI: 10.3390/jcm11020305. PMID: 35054000; PMCID: PMC8780875.
News
La tercera edició del PERIS torna a finançar un projecte de Germans Trias i Pujol
El Departament de Salut ha lliurat aquest dimarts els ajuts de les convocatòries 2018 i 2019 del Pla Estratègic de Recerca i Innovació en Salut (PERIS). En l'edició d'enguany, la neuròloga de Germans Trias Natalia Pérez de la Ossa ha obtingut un ajut pel projecte d'atenció prehospitalària de pacients amb ictus agut. També el metge Daniel Fuster, que va rebre un ajut en la segona edició del PERIS, ha recollit aquest dimarts el guardó.
Revisió sobre les recomanacions de consum d’alcohol en pacients amb malalties hepàtiques
El Dr. Daniel Fuster de la Unitat d'Addiccions, al Servei de Medicina Interna de l'Hospital Universitari Germans Trias i Pujol i l'Institut de Recerca (IGTP), és coautor d'un article de revisió històrica sobre l'ús d'alcohol amb pacients amb malalties hepàtiques cròniques, juntament amb el Dr. Jeffrey H Samet, al Boston Medical Center i University School of Medicine. L'article s'ha publicat a la revista New England Journal of Medicine.
Contact
Robert Muga Bustamante
(+34) 93 465 12 00 extn. 3582
More links
Blog · Follow @hugtipAdd on Twitter · Donate via Amics de Can Ruti